BromhexIne And Spironolactone For CoronŠ°VirUs Infection Requiring HospiTalization
Status:
Recruiting
Trial end date:
2020-08-23
Target enrollment:
Participant gender:
Summary
Patients with mild and severe COVID 19 will be randomized 1:1 into two groups: experimental,
which will get bromhexine and spironolactone, and control. Patients will get investigated
therapy for ten days. Change in clinical assessment score COVID 19 (CAS COVID 19) between
baseline and 12th day will be evaluated as a primary endpoint. Forty-five-day risk of death
or mechanical ventilation will also be assessed.
Phase:
Phase 3
Details
Lead Sponsor:
Lomonosov Moscow State University Medical Research and Educational Center